• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雄激素受体变体 AR-V7 的活性受到 FOXO1 的调控，这种调控方式依赖于 PTEN-PI3K-AKT。

The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

机构信息

Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.

出版信息

Prostate. 2013 Feb 15;73(3):267-77. doi: 10.1002/pros.22566. Epub 2012 Jul 20.

DOI:10.1002/pros.22566
PMID:22821817
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3961010/
Abstract

BACKGROUND

The androgen receptor (AR) AR-V7 splice isoform is a constitutively active outlaw transcription factor. Transition of prostate cancer (PC) to the castration-resistant phenotype correlates with AR-V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform. The mechanism of AR-V7 constitutive activation is not known.

METHODS

We analyzed potential signaling pathways associated with AR-V7 constitutive activation in PTEN (-) PC-3 and LNCaP cells. We used transient and stable transfection, reporter gene assay, RNAi technology together with a number of kinase inhibitors to determine if AR-V7 activation is linked to a kinase-dependent signaling pathway.

RESULTS

In these cell lines, AR-V7 transcriptional activity was inhibited by LY294002, Wortmanin, and AKT inhibitor II. Analysis of the contributing mechanisms demonstrated the involvement of the Phosphatidylinositol 3-kinase (PI3K)-AKT-FOXO1 signaling pathway, and a significant reduction of AR-V7 constitutive activity under conditions of PTEN reactivation.

CONCLUSIONS

Our study identifies a pathway regulating AR-V7 constitutive activity and potential therapeutic targets for the treatment of castration-resistant PC.

摘要

背景

雄激素受体 (AR) AR-V7 剪接异构体是一种组成型激活的非法转录因子。前列腺癌 (PC) 向去势抵抗表型的转变与 AR-V7 的积累相关，这表明在对常规治疗有抗药性的患者中，PC 的进展是由于这种 AR 异构体的活性。AR-V7 组成型激活的机制尚不清楚。

方法

我们分析了与 PTEN(-)PC-3 和 LNCaP 细胞中 AR-V7 组成型激活相关的潜在信号通路。我们使用瞬时和稳定转染、报告基因检测、RNAi 技术以及多种激酶抑制剂来确定 AR-V7 的激活是否与依赖激酶的信号通路有关。

结果

在这些细胞系中，LY294002、Wortmanin 和 AKT 抑制剂 II 抑制了 AR-V7 的转录活性。对促成机制的分析表明，磷酸肌醇 3-激酶 (PI3K)-AKT-FOXO1 信号通路的参与，以及在 PTEN 重新激活的条件下，AR-V7 组成型活性的显著降低。

结论

我们的研究确定了调节 AR-V7 组成型活性的途径，并为治疗去势抵抗性 PC 提供了潜在的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/b85403a73455/nihms-391269-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/08bb38a74a77/nihms-391269-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/ba6f63ffb348/nihms-391269-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/f6e6d75f73bd/nihms-391269-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/209bba0e83c0/nihms-391269-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/9cfd801f2416/nihms-391269-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/e6a98db7c09c/nihms-391269-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/3155ad8c5677/nihms-391269-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/ed0dbe96ec70/nihms-391269-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/b85403a73455/nihms-391269-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/08bb38a74a77/nihms-391269-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/ba6f63ffb348/nihms-391269-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/f6e6d75f73bd/nihms-391269-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/209bba0e83c0/nihms-391269-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/9cfd801f2416/nihms-391269-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/e6a98db7c09c/nihms-391269-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/3155ad8c5677/nihms-391269-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/ed0dbe96ec70/nihms-391269-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb0/3961010/b85403a73455/nihms-391269-f0009.jpg

相似文献

1
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.雄激素受体变体 AR-V7 的活性受到 FOXO1 的调控，这种调控方式依赖于 PTEN-PI3K-AKT。
Prostate. 2013 Feb 15;73(3):267-77. doi: 10.1002/pros.22566. Epub 2012 Jul 20.
2
Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.PI3K/AKT抑制剂对前列腺癌细胞中雄激素受体基因表达的复杂影响。
PLoS One. 2014 Oct 31;9(10):e108780. doi: 10.1371/journal.pone.0108780. eCollection 2014.
3
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.FOXO1 与 TAU5 基序结合，抑制组成型激活的雄激素受体剪接变体。
Prostate. 2013 Jul;73(10):1017-27. doi: 10.1002/pros.22649. Epub 2013 Feb 6.
4
Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.PI3K/AKT、PTEN/FOXO 和 AR 信号在前列腺癌中的相互作用。
Adv Exp Med Biol. 2019;1210:319-331. doi: 10.1007/978-3-030-32656-2_14.
5
Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.褪黑素抑制雄激素受体剪接变体7（AR-V7）诱导的核因子-κB（NF-κB）激活以及NF-κB激活剂诱导的前列腺癌细胞中AR-V7的表达：褪黑素在去势抵抗性前列腺癌（CRPC）治疗中应用的潜在意义。
Int J Mol Sci. 2017 May 31;18(6):1130. doi: 10.3390/ijms18061130.
6
Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells.白藜芦醇通过激活前列腺癌细胞中的 FOXO 转录因子诱导细胞生长停滞和凋亡。
PLoS One. 2010 Dec 14;5(12):e15288. doi: 10.1371/journal.pone.0015288.
7
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.抑制雄激素受体作为紫杉醇治疗前列腺癌的新机制。
Cancer Res. 2009 Nov 1;69(21):8386-94. doi: 10.1158/0008-5472.CAN-09-1504. Epub 2009 Oct 13.
8
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.PI3K/AKT 抑制剂联合雄激素剥夺治疗在前列腺癌临床前模型中的高效性。
Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.
9
Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.青蒿素通过刺激26S蛋白酶体介导的雄激素受体蛋白降解，破坏人前列腺癌细胞的雄激素反应性。
Anticancer Drugs. 2017 Oct;28(9):1018-1031. doi: 10.1097/CAD.0000000000000547.
10
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.磷脂酰肌醇3激酶/蛋白激酶B下游底物FOXO3a诱导雄激素受体表达及其在LNCaP前列腺癌细胞凋亡中的作用。
J Biol Chem. 2005 Sep 30;280(39):33558-65. doi: 10.1074/jbc.M504461200. Epub 2005 Aug 1.

引用本文的文献

1
Pleckstrin-2 Mediates the Activation of AKT in Prostate Cancer and Is Repressed by Androgen Receptor.Pleckstrin-2 介导体前列腺癌细胞中 AKT 的激活，且受雄激素受体抑制。
Am J Pathol. 2024 Oct;194(10):1986-1996. doi: 10.1016/j.ajpath.2024.07.004. Epub 2024 Jul 26.
2
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.与前列腺癌进展相关的分子生物标志物的调控
Int J Mol Sci. 2024 Apr 10;25(8):4171. doi: 10.3390/ijms25084171.
3
Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT.

本文引用的文献

1
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.在去势抵抗性前列腺癌中，使用阿比特龙抑制 CYP17A1 产生耐药性：诱导甾体生成和雄激素受体剪接变体。
Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.
2
Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.用提高性能（抗）类固醇增强前列腺癌治疗。
Cancer Cell. 2011 Jul 12;20(1):7-9. doi: 10.1016/j.ccr.2011.06.019.
3
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
阿魏酸苯乙酯通过抑制 CDK1 和 AKT 抑制雄激素受体变体 7 的表达。
Cancer Gene Ther. 2024 Jun;31(6):807-815. doi: 10.1038/s41417-024-00753-z. Epub 2024 Mar 13.
4
A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer.雄激素受体变体7靶基因及其在去势抵抗性前列腺癌中的作用简编
Front Oncol. 2023 Mar 1;13:1129140. doi: 10.3389/fonc.2023.1129140. eCollection 2023.
5
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer.AR-V7在去势抵抗性前列腺癌恩杂鲁胺耐药中的关键作用
Cancers (Basel). 2022 Oct 5;14(19):4877. doi: 10.3390/cancers14194877.
6
Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer.PI3K 和 AR 通路中的基因表达改变以及 DNA 甲基化特征导致前列腺癌的转移。
Cell Mol Life Sci. 2022 Jul 21;79(8):436. doi: 10.1007/s00018-022-04456-2.
7
Inhibition of -Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication.乙酰基转移酶 10 的抑制通过调节 DNA 复制抑制前列腺癌的进展。
Int J Mol Sci. 2022 Jun 12;23(12):6573. doi: 10.3390/ijms23126573.
8
Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.布鲁斯汀通过靶向 HSP90 克服去势抵抗性前列腺癌对激素治疗的耐药性。
Theranostics. 2021 Jan 1;11(2):958-973. doi: 10.7150/thno.51478. eCollection 2021.
9
Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis.采用全比较磷酸化蛋白质组分析鉴定与 PC-3M 细胞迁移增加相关的激酶表达特征。
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):543-553. doi: 10.21873/cgp.20210.
10
Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.肌醇多聚磷酸 4-磷酸酶 II 对雄激素受体活性的调节。
Oncogene. 2019 Feb;38(7):1121-1135. doi: 10.1038/s41388-018-0498-3. Epub 2018 Sep 18.
癌症统计数据，2011 年：消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
4
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.PTEN 缺陷型前列腺癌中 PI3K 和雄激素受体信号的相互反馈调节。
Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008.
5
Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.针对前列腺癌中肿瘤起始细胞和分化细胞群体的联合治疗。
Clin Cancer Res. 2010 Dec 1;16(23):5692-702. doi: 10.1158/1078-0432.CCR-10-1601.
6
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.在去势抵抗性前列腺癌中表达的组成性激活的雄激素受体剪接变体需要全长雄激素受体。
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.
7
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.在人类前列腺癌中，雄激素受体剪接变体的频繁发生导致去势抵抗。
J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.
8
Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine.与雄激素不敏感综合征相关的雄激素受体突变：一种高内涵分析方法，可实现个体化医疗。
PLoS One. 2009 Dec 9;4(12):e8179. doi: 10.1371/journal.pone.0008179.
9
Targeting the phosphoinositide 3-kinase pathway in cancer.靶向癌症中的磷酸肌醇3-激酶通路。
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
10
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.一种新型雄激素受体剪接变体在前列腺癌进展过程中上调，并促进抗雄激素耗竭的生长。
Cancer Res. 2009 Mar 15;69(6):2305-13. doi: 10.1158/0008-5472.CAN-08-3795. Epub 2009 Feb 24.